{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreighivqjjelnekjatzdsvxxg2mhtbwrtjrloyoei5ts7tdiy3sdvum",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfssinr7vqc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiabne5q74twx2w3krdc5syvblb4lku55imuanuwgifxibpca5xz4m"
    },
    "mimeType": "image/jpeg",
    "size": 91475
  },
  "path": "/2026/02/26/biotech-news-fda-rejection-for-rare-blood-cancer-therapy/?utm_campaign=rss",
  "publishedAt": "2026-02-26T14:37:38.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "Sarepta CEO steps down, an experimental cell therapy rejection, and more biotech news",
  "title": "STAT+: FDA rejection is a reality check on agency rhetoric",
  "updatedAt": "2026-02-26T14:37:42.000Z"
}